Neptune Announces Third Quarter Results LAVAL, Quebec, Jan.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Neptune Announces Third Quarter Results

LAVAL, Quebec, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq: NEPT ) (TSX: NTB ), announces its consolidated financial results for the three and nine month periods ended November 30, 2014.

"We made solid progress on all fronts this past quarter, completing the ramp-up of production at our Sherbrooke plant, resuming shipments of Neptune manufactured krill oil, and announcing the appointment of nutraceutical industry leader, Mr. Jim Hamilton, as Neptune's new President and CEO, effective February 2015," highlighted Mr. André Godin, Interim President and Chief Executive Officer of Neptune. "On top of this, our subsidiary, Acasti, announced positive results for its Phase II double-blind TRIFECTA and Pharmacokinetic trials, taking us one step closer to commencing a Phase III trial in North America. We believe that this positive momentum gives the Neptune group a strong foundation for the future."

Third Quarter Financial Results

Nutraceutical Business Results

  • Nutraceutical revenues were $4,706,000 for the three-month period ended November 30, 2014, up from $4,440,000 for the three-month period ended November 30, 2013
  • Adjusted EBITDA was negative ($1,957,000) for the current quarter, improving over negative ($4,176,000) in the prior year
  • Net loss was ($3,241,000) for the current quarter, versus ($6,887,000) in the prior year.

Consolidated Results

  • Consolidated revenues totalled $4,735,000 for the three-month period ended November 30, 2014, up from $4,468,000 for the quarter ended November 30, 2013
  • Adjusted gross margin 1 as a percent of revenue was 27% for the current quarter, versus 14% for the corresponding prior year quarter
  • Adjusted EBITDA was negative ($4,315,000) for the current quarter, versus negative ($5,912,000) in the prior year
  • Net income was $74,000 for the current quarter, versus a net loss of ($10,443,000) in the prior year
  • Cash and short-term investments were $34.6 million as at November 30, 2014. 

1 The adjusted gross margin excludes non-recurring costs included in the cost of sales, namely incremental costs related to the plant ramp-up of $854,000 for the quarter ended November 30, 2014.

Nutraceutical revenues for the quarter ending November 30, 2014 were largely derived from the sale of Neptune manufactured krill oil and partially through the sale of oil obtained through Neptune's third party supply agreement.

The year over year improvement in adjusted EBITDA, on both a nutraceutical and consolidated basis, is largely due to lower professional fees. On a consolidated basis the current quarter includes adjusted EBITDA of negative $2.4 million for Neptune's subsidiaries. This includes $2.1 million for Acasti, which is actively engaged in clinical studies and research and development.  In the corresponding prior year quarter, Neptune's subsidiaries recorded negative $1.7 million of adjusted EBITDA.

The lower year over year nutraceutical net loss is largely due to a decrease in stock based compensation expenses and professional fees as well as a foreign exchange gain resulting from the devaluation of the Canadian dollar over the US dollar. On a consolidated basis, Neptune's subsidiaries recorded net income of $3.3 million for the current quarter and a net loss of $3.6 million for the corresponding prior year quarter. The consolidated quarterly net income for the current quarter was derived by the aforesaid nutraceutical gains, along with an increase in finance income attributable to the re-evaluation of the warrant liabilities related to Acasti's December 2013 public offering. 

Year-to-Date Financial Results

Nutraceutical Business Results

  • Nutraceutical revenues were $10,957,000 for the nine-month period ended November 30, 2014, versus $15,605,000 for the nine-month period ended November 30, 2013
  • Adjusted EBITDA was negative ($15,853,000) for the nine-month period ended November 30, 2014, versus negative ($10,953,000) for the corresponding prior-year period
  • Net loss was ($20,299,000) for the nine-month period ended November 30, 2014, compared to net loss of ($12,045,000) for the corresponding prior-year period.

Consolidated Results

  • Consolidated revenues totalled $11,049,000 for the nine-month period ended November 30, 2014, compared to $15,906,000 for the corresponding prior-year period
  • Adjusted EBITDA was negative ($22,962,000) for the nine-month period ended November 30, 2014, versus negative ($15,951,000) for the corresponding prior-year period
  • Net loss was ($19,143,000) for the nine-month period ended November 30, 2014, versus a net loss of ($20,910,000) in the corresponding prior-year period.

Sherbrooke Plant

On November 5, 2014, Neptune announced that its Sherbrooke plant had successfully completed its ramp-up and had reached full production capacity of 150 metric tons annually. "Sales momentum continues to build and with production of new condition-specific formulations commencing by the end of our fourth quarter ending February 28, 2015, we anticipate greater sales opportunities going forward," highlighted Mr. Godin. 

As previously stated, Neptune expects that by around mid-2015 annualized demand for Neptune's manufactured krill oil will be at approximately 150 metric tons. Given this, a formal program has been created to increase plant efficiencies and optimize processes in order to increase production capacity, using as little capital as possible. 

USPTO review of Neptune's '351 Patent

During the quarter ended November 30, 2014, the inter partes review proceedings before the U.S. Patent and Trademark Office (USPTO) regarding certain claims of Neptune's '351 composition of matter patent took place and a decision is expected to be rendered by mid-March 2015. As previously announced, Neptune's royalty bearing license agreements with Aker BioMarine and Enzymotec are dependent on the outcome of the USPTO review. Neptune continues to believe it is well positioned to prevail.

Normal Course Issuer Bid

In October 2014, Neptune announced that its Board of Directors approved a normal course issuer bid (NCIB) to repurchase for cancellation up to 1,500,000 of its common shares, representing approximately 2% of the Corporation's issued and outstanding common shares as of August 31, 2014. The NCIB lasts for one year and ends on October 30, 2015 or on such earlier date as Neptune has purchased the maximum shares permissible or otherwise decided not to make any further repurchases under the NCIB.  As at January 13, 2015, no shares had been purchased in connection with the NCIB.

NeuroBioPharm to be indirectly privatized by Neptune - Enters into Arrangement Agreement with Neptune

Neptune and NeuroBioPharm Inc. (NeuroBio) announced that they have entered into an arrangement agreement which will result in the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio, under terms described in more detail in the joint press release issued today. It is anticipated that the holders of NeuroBio Securities will benefit from the completion of the Arrangement in that such holders will receive Neptune Securities as consideration for their NeuroBio Securities. As shareholders of Neptune, they will also continue to participate in any value increases associated with NeuroBio and will benefit from owning shares in a larger public company with increased size, scale and liquidity.

Conference Call Details

Neptune will be holding a conference call on Wednesday January 14 at 9:00 AM (ET) to present its results for the third quarter ended November 30, 2014. 

Date: Wednesday January 14, 2015
   
Time:  9:00 AM Eastern Time
   
Conference ID: 56159709
   
Call: 1‐877-380-5664 (within Canada & the U.S.)
  1-631-813-4882 (Outside Canada and the U.S.)
  (Please dial in 15 minutes before the call begins)
   
Webcast: A live audio webcast can be accessed at:   http://neptunekrilloil.com/investors/investor...entations/

An archived recording of the conference call will also be available on Neptune's website shortly after the call.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (''PUFAs''). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune's products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune's head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune holds approximately 48% of the participating and voting rights of Acasti Pharma Inc. ("Acasti") and 95% of the voting rights of NeuroBioPharm Inc. ("NeuroBio"). Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBioPharm respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti's lead prescription drug candidate is CaPre ® , a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties,   readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form, which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com , on EDGAR at www.sec.gov/edgar.shtml  and on the investor section of Neptune's website at www.neptunebiotech.com  (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors".

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

Neptune Contacts: Andre Godin Interim CEO and CFO +1.450.687.2262 neptunebiotech.com John Ripplinger Investor Relations +1.450.687.2262 neptunebiotech.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 0

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 23

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 102

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 41

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading

Top 5 Most Recently Viewed Articles

Flow Beverage Welcomes José Bautista as Advisor and Announces Fundraising Progress

Updated Category News Views 336

Flow Beverage Corp. Welcomes José Bautista as Strategic Advisor Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) has recently made a significant move by bringing on board José Bautista as a Strategic Advisor. This addition is seen as a promising enhancement to the company's team, aligning with its dedication to excellence and innovation in the beverage sector. Background of...

Continue Reading
Milan Laser Hair Removal Marks a Significant 400 Clinic Milestone

Updated Category News Views 207

Milan Laser Hair Removal Reaches 400 Clinics Nationwide The leading provider in laser hair removal achieves a remarkable milestone with nationwide expansion efforts. Milan Laser Hair Removal, the hallmark of laser hair removal in the nation, proudly celebrates the grand opening of its 400th clinic, symbolizing a major advancement in its rapid expansion across the country....

Continue Reading
Global Vertical Roller Mill Market Expands to USD 1.04 Billion

Updated Category News Views 215

Understanding the Global Vertical Roller Mill Market The Vertical Roller Mill (VRM) market is anticipated to experience significant growth in the coming years. Currently valued at approximately USD 608.5 million in 2024, projections indicate that it will reach USD 1,041.2 million by 2033, achieving a compound annual growth rate (CAGR) of 6.1%. This increase is largely due...

Continue Reading
Pulsar Helium Provides Insights on Progress at Topaz Project

Updated Category News Views 313

Pulsar Helium Develops Well-Testing Strategy at Topaz Project Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF), a leading helium development company, has recently provided valuable updates regarding its well-testing activities at the Topaz project, located in Minnesota. This momentous phase in the project holistically aims to assess helium extraction capabilities...

Continue Reading
Trade Disclosures: Treatt plc's Key Operations Analyzed

Updated Category News Views 178

Understanding Recent Trade Disclosures by Treatt plc Treatt plc, a company known for its expertise in manufacturing and distributing essential oils and flavouring agents, operates in a competitive sector where trade disclosures play a crucial role in maintaining transparency and building investor trust. As we delve into the recent disclosures made by Treatt plc, we'll...

Continue Reading